H2AB3

Summary

H2AB3 (H2A.B variant histone 3, HGNC:14455) is a protein-coding gene on chromosome Xq28, encoding Histone H2A-Bbd type 2/3 (P0C5Z0). Atypical histone H2A which can replace conventional H2A in some nucleosomes and is associated with active transcription and mRNA processing.

Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Nucleosomes consist of approximately 146 bp of DNA wrapped around a histone octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. This gene encodes a replication-independent histone that is a member of the histone H2A family. This gene is part of a region that is repeated three times on chromosome X, once in intron 22 of the F8 gene and twice closer to the Xq telomere. This record represents the most telomeric copy.

Source: NCBI Gene 83740 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_080720

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14455
Approved symbol	H2AB3
Name	H2A.B variant histone 3
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	H2A.B.1
Ensembl gene	ENSG00000277745
Ensembl biotype	protein_coding
OMIM	300445
Entrez	83740

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000615853

RefSeq mRNA: 1 — MANE Select: NM_080720 NM_080720

CCDS: CCDS35464

Canonical transcript exons

ENST00000615853 — 1 exons

Exon	Start	End
ENSE00003712641	155459415	155460005

Expression profiles

Bgee: expression breadth ubiquitous, 104 present calls, max score 84.74.

Top tissues by expression

131 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.74	gold quality
right coronary artery	UBERON:0001625	53.38	gold quality
right testis	UBERON:0004534	50.79	gold quality
right ovary	UBERON:0002118	49.96	gold quality
left uterine tube	UBERON:0001303	47.30	gold quality
spleen	UBERON:0002106	47.09	gold quality
blood	UBERON:0000178	46.46	gold quality
mucosa of stomach	UBERON:0001199	45.86	gold quality
endocervix	UBERON:0000458	45.12	gold quality
duodenum	UBERON:0002114	45.05	gold quality
left adrenal gland cortex	UBERON:0035825	44.19	gold quality
muscle layer of sigmoid colon	UBERON:0035805	44.04	gold quality
sural nerve	UBERON:0015488	44.02	gold quality
ganglionic eminence	UBERON:0004023	43.54	gold quality
cortical plate	UBERON:0005343	43.08	gold quality
testis	UBERON:0000473	43.01	gold quality
descending thoracic aorta	UBERON:0002345	42.97	gold quality
ascending aorta	UBERON:0001496	41.94	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	41.87	gold quality
thoracic aorta	UBERON:0001515	41.82	gold quality
gastrocnemius	UBERON:0001388	41.21	gold quality
lower esophagus	UBERON:0013473	41.20	gold quality
muscle of leg	UBERON:0001383	41.18	gold quality
left coronary artery	UBERON:0001626	41.17	gold quality
lower esophagus muscularis layer	UBERON:0035833	41.11	gold quality
omental fat pad	UBERON:0010414	40.92	gold quality
left testis	UBERON:0004533	40.68	gold quality
skeletal muscle tissue	UBERON:0001134	40.62	gold quality
ovary	UBERON:0000992	40.61	gold quality
primary visual cortex	UBERON:0002436	40.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.23

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting H2AB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-363-5P	99.46	64.51	1015
HSA-MIR-128-1-5P	99.33	60.46	332
HSA-MIR-128-2-5P	99.33	60.83	311
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-4260	98.78	65.37	848
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-6796-5P	95.37	66.08	1120
HSA-MIR-2861	95.24	65.47	1056
HSA-MIR-6781-5P	94.61	59.49	155
HSA-MIR-492	94.02	64.46	413

Literature-anchored findings (GeneRIF, showing 1)

• data suggest that H2ABbd may contribute to specific chromatin structures and promote NF-kappaB activation, which could in turn induce apoptosis in mammalian cells (PMID:24584930)

Cross-species orthologs

24 orthologs

Organism	Symbol	Gene ID
mus_musculus	H2ab1	ENSMUSG00000067441
mus_musculus	H2ab2	ENSMUSG00000082482
mus_musculus	H2ab3	ENSMUSG00000083616
rattus_norvegicus	H2ab3	ENSRNOG00000029736
drosophila_melanogaster	His2A:CG31618	FBGN0051618
drosophila_melanogaster	His2A:CG33808	FBGN0053808
drosophila_melanogaster	His2A:CG33814	FBGN0053814
drosophila_melanogaster	His2A:CG33817	FBGN0053817
drosophila_melanogaster	His2A:CG33820	FBGN0053820
drosophila_melanogaster	His2A:CG33823	FBGN0053823
drosophila_melanogaster	His2A:CG33826	FBGN0053826
drosophila_melanogaster	His2A:CG33829	FBGN0053829
drosophila_melanogaster	His2A:CG33832	FBGN0053832
drosophila_melanogaster	His2A:CG33835	FBGN0053835
drosophila_melanogaster	His2A:CG33838	FBGN0053838
drosophila_melanogaster	His2A:CG33841	FBGN0053841
drosophila_melanogaster	His2A:CG33844	FBGN0053844
drosophila_melanogaster	His2A:CG33847	FBGN0053847
drosophila_melanogaster	His2A:CG33850	FBGN0053850
drosophila_melanogaster	His2A:CG33853	FBGN0053853
drosophila_melanogaster	His2A:CG33856	FBGN0053856
drosophila_melanogaster	His2A:CG33859	FBGN0053859
drosophila_melanogaster	His2A:CG33862	FBGN0053862
drosophila_melanogaster	His2A:CG33865	FBGN0053865

Paralogs (27): MACROH2A2 (ENSG00000099284), H2AZ2 (ENSG00000105968), MACROH2A1 (ENSG00000113648), H2AZ1 (ENSG00000164032), H2AC1 (ENSG00000164508), H2AC6 (ENSG00000180573), H2AC25 (ENSG00000181218), H2AC20 (ENSG00000184260), H2AC21 (ENSG00000184270), H2AX (ENSG00000188486), H2AC13 (ENSG00000196747), H2AC11 (ENSG00000196787), H2AC7 (ENSG00000196866), H2AL3 (ENSG00000229674), H2AJ (ENSG00000246705), H2AL1Q (ENSG00000249467), H2AB1 (ENSG00000274183), H2AC12 (ENSG00000274997), H2AC15 (ENSG00000275221), H2AC14 (ENSG00000276368), H2AC16 (ENSG00000276903), H2AC8 (ENSG00000277075), H2AB2 (ENSG00000277858), H2AC4 (ENSG00000278463), H2AC17 (ENSG00000278677), H2AC18 (ENSG00000288825), H2AC19 (ENSG00000288859)

Protein

Protein identifiers

Histone H2A-Bbd type 2/3 — P0C5Z0 (reviewed: P0C5Z0)

Alternative names: H2A Barr body-deficient

All UniProt accessions (1): P0C5Z0

UniProt curated annotations — full annotation on UniProt →

Function. Atypical histone H2A which can replace conventional H2A in some nucleosomes and is associated with active transcription and mRNA processing. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. Nucleosomes containing this histone are less rigid and organize less DNA than canonical nucleosomes in vivo. They are enriched in actively transcribed genes and associate with the elongating form of RNA polymerase. They associate with spliceosome components and are required for mRNA splicing. May participate in spermatogenesis.

Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. May be incorporated into a proportion of nucleosomes, replacing one or more H2A molecules.

Subcellular location. Nucleus. Chromosome.

Tissue specificity. Present in mature sperm.

Domain organisation. The docking domain is responsible for the weaker heterodimerization with H2B.

Miscellaneous. In contrast to other H2A histones, it does not contain the conserved residues that are the target of post-translational modifications.

Similarity. Belongs to the histone H2A family.

RefSeq proteins (1): NP_542451* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002119	Histone_H2A	Family
IPR009072	Histone-fold	Homologous_superfamily

UniProt features (12 total): helix 5, strand 4, region of interest 2, chain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
6A7U	X-RAY DIFFRACTION	2.6
6M4G	ELECTRON MICROSCOPY	2.8
9II7	ELECTRON MICROSCOPY	3.5
6M4H	ELECTRON MICROSCOPY	3.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0C5Z0-F1	87.38	0.76

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 27 (showing top): GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_CHROMATIN_REMODELING, GOBP_HETEROCHROMATIN_ORGANIZATION, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, GOCC_PROTEIN_DNA_COMPLEX, GOCC_EUCHROMATIN, GOMF_PROTEIN_HETERODIMERIZATION_ACTIVITY, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, chrXq28, GOBP_NUCLEOSOME_ORGANIZATION, GOBP_MRNA_PROCESSING

GO Biological Process (3): nucleosome assembly (GO:0006334), mRNA processing (GO:0006397), heterochromatin formation (GO:0031507)

GO Molecular Function (4): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (4): nucleosome (GO:0000786), euchromatin (GO:0000791), nucleus (GO:0005634), chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
chromatin	3
chromatin organization	1
nucleosome organization	1
protein-DNA complex assembly	1
RNA processing	1
mRNA metabolic process	1
cellular component assembly	1
heterochromatin boundary formation	1
negative regulation of gene expression, epigenetic	1
heterochromatin organization	1
nucleic acid binding	1
structural molecule activity	1
protein dimerization activity	1
binding	1
protein-DNA complex	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

920 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
H2AB3	H4C7	Q99525	664
H2AB3	H4C16	P02304	640
H2AB3	CENPA	P49450	610
H2AB3	H3Y2	P0DPK5	587
H2AB3	H2BC21	Q16778	587
H2AB3	H3Y1	P0DPK2	584
H2AB3	H1-0	P07305	510
H2AB3	H3C1	P02295	451
H2AB3	H2BC1	Q96A08	439
H2AB3	H1-8	Q8IZA3	418
H2AB3	H1-7	Q75WM6	406
H2AB3	H3-4	Q16695	402
H2AB3	GMCL2	Q8NEA9	390
H2AB3	H3-3A	P06351	389
H2AB3	H1-6	P22492	388

IntAct

12 interactions, top by confidence:

A	B	Type	Score
H2BC13	H2AB2	psi-mi:“MI:0915”(physical association)	0.560
H2AB2	H2BC15	psi-mi:“MI:0915”(physical association)	0.560
H2AB2	H2BC13	psi-mi:“MI:0915”(physical association)	0.560
H2AB2	MESD	psi-mi:“MI:0915”(physical association)	0.560
SLC16A11	H2AB2	psi-mi:“MI:0914”(association)	0.530
H2AB2	H2BC15	psi-mi:“MI:0915”(physical association)	0.000
H2AB2	MESD	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (242): H2AFB3 (Affinity Capture-MS), H2AFB3 (Two-hybrid), H2AFB2 (Two-hybrid), H2AFB3 (Two-hybrid), H2AFB2 (Two-hybrid), H2AFB3 (Two-hybrid), H2AFB2 (Two-hybrid), SRRM1 (Affinity Capture-MS), CDK13 (Affinity Capture-MS), DKC1 (Affinity Capture-MS), FTSJ3 (Affinity Capture-MS), UTP3 (Affinity Capture-MS), PAIP2B (Affinity Capture-MS), ZCCHC6 (Affinity Capture-MS), GNL3 (Affinity Capture-MS)

ESM2 similar proteins: A0A1W2PP81, A0A1W2PPE2, A0A1W2PPH5, A0A1W2PPL8, A0A1W2PR64, A0A1W2PRV1, A0A3B3IU63, A4QVR2, A5DQL2, A9UMV8, F4HR03, O35216, P06898, P0C1H6, P0C5Y9, P0C5Z0, P0DW11, P0DW12, P0DW13, P0DW14, P0DW85, P35061, P48003, P49450, Q00728, Q3SZB8, Q3ZBX9, Q4IMD1, Q5M8Q2, Q5TKR9, Q64522, Q64598, Q7Z2G1, Q803H4, Q873G4, Q8BRB7, Q8BZ21, Q8CGP5, Q8IUE6, Q8R1M2

Diamond homologs: A0A3B3IU63, A1A4R1, A2WQG7, A5DBG4, A5DJJ2, A5DXS8, A9UMV8, C0HKE1, C0HKE2, C0HKE3, C0HKE4, C0HKE5, C0HKE6, C0HKE7, C0HKE8, C0HKE9, P02262, P02263, P02264, P02269, P02270, P02273, P02274, P02276, P02277, P04908, P06897, P07793, P09588, P0C0S8, P0C0S9, P0C169, P0C170, P0C5Y9, P0C5Z0, P0CC09, P0CN98, P0CN99, P13630, P13912

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SLBP	“up-regulates quantity by expression”	H2AB2	“translation regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

128 predictions. Top by Δscore:

Variant	Effect	Δscore
X:155459915:T:TA	donor_gain	0.9300
X:155459918:T:TA	donor_gain	0.9200
X:155459747:CAATA:C	donor_gain	0.8800
X:155459748:AATAA:A	donor_gain	0.8800
X:155459748:A:AC	donor_gain	0.8100
X:155459835:T:C	donor_gain	0.7200
X:155459745:CTCAA:C	donor_gain	0.7100
X:155459746:TCAAT:T	donor_gain	0.7100
X:155459834:C:CC	acceptor_gain	0.7000
X:155459822:C:CT	donor_gain	0.6800
X:155459823:C:CT	donor_gain	0.6800
X:155459889:A:AC	donor_gain	0.6800
X:155459821:TC:T	donor_gain	0.6700
X:155459635:AGTAG:A	donor_gain	0.6400
X:155459723:CCAGG:C	donor_gain	0.6300
X:155459785:AGGCG:A	donor_gain	0.6200
X:155459807:C:A	donor_gain	0.6200
X:155459744:A:AC	donor_gain	0.6100
X:155459745:C:CC	donor_gain	0.6100
X:155459991:G:C	donor_gain	0.5900
X:155459638:AG:A	donor_gain	0.5600
X:155459785:AGG:A	donor_gain	0.5500
X:155459829:G:A	donor_gain	0.5500
X:155459830:CTCA:C	acceptor_gain	0.5500
X:155459654:C:CT	donor_gain	0.5400
X:155459786:G:C	donor_gain	0.5300
X:155459989:CAG:C	donor_gain	0.5300
X:155459831:TCA:T	acceptor_gain	0.5200
X:155459832:CAC:C	acceptor_gain	0.5200
X:155459912:T:TA	donor_gain	0.5200

AlphaMissense

720 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:155459838:A:C	F30L	0.950
X:155459838:A:T	F30L	0.950
X:155459840:A:G	F30L	0.950
X:155459622:G:C	F102L	0.873
X:155459622:G:T	F102L	0.873
X:155459624:A:G	F102L	0.873
X:155459735:C:G	A65P	0.803
X:155459839:A:G	F30S	0.801
X:155459756:C:G	A58P	0.797
X:155459680:A:G	I83T	0.788
X:155459716:G:T	A71E	0.750
X:155459755:G:T	A58E	0.736
X:155459860:G:A	T23I	0.733
X:155459705:C:G	A75P	0.725
X:155459653:A:T	V92D	0.724
X:155459740:A:G	L63P	0.716
X:155459781:A:C	S49R	0.715
X:155459781:A:T	S49R	0.715
X:155459783:T:G	S49R	0.715
X:155459758:G:T	A57D	0.713
X:155459680:A:C	I83S	0.712
X:155459765:A:C	Y55D	0.711
X:155459717:C:G	A71P	0.710
X:155459728:A:T	V67D	0.702
X:155459746:T:A	E61V	0.682
X:155459839:A:C	F30C	0.680
X:155459818:C:G	R37P	0.669
X:155459752:A:T	V59D	0.667
X:155459829:G:C	S33R	0.666
X:155459829:G:T	S33R	0.666

dbSNP variants (sampled 72 via entrez): RS1172470193 (X:155459010 C>A,G), RS1173128502 (X:155458971 A>C,G), RS1175078700 (X:155459030 C>T), RS1192481441 (X:155458989 A>C,G), RS1207044841 (X:155458998 C>T), RS12389952 (X:155461387 C>T), RS12390268 (X:155458987 G>A), RS12390269 (X:155458988 G>C), RS1272785202 (X:155459002 C>A,G), RS1281543188 (X:155459006 C>A,G,T), RS1301257899 (X:155459004 C>A,G,T), RS1334590295 (X:155459008 C>A,G), RS1350704389 (X:155459003 C>G), RS1353663082 (X:155459007 C>A,G), RS1373557388 (X:155459009 C>G)

Disease associations

OMIM: gene MIM:300445 | disease phenotypes: MIM:134500, MIM:306700

GenCC curated gene-disease

Mondo (1): hemophilia A (MONDO:0010602)

Orphanet (1): Hemophilia A (Orphanet:98878)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006467	Hemophilia A	C15.378.100.100.500; C15.378.100.141.500; C15.378.463.500; C16.320.099.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
licochalcone B	increases expression	1
Decitabine	decreases expression, decreases reaction	1
Rotenone	decreases expression	1
Smoke	decreases expression, decreases reaction	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00002386	PHASE4	COMPLETED	Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
NCT00092976	PHASE4	COMPLETED	Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
NCT00151385	PHASE4	WITHDRAWN	Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00168051	PHASE4	WITHDRAWN	Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00243386	PHASE4	COMPLETED	Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00284193	PHASE4	COMPLETED	Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
NCT00289536	PHASE4	COMPLETED	Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00357656	PHASE4	COMPLETED	Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
NCT00586521	PHASE4	COMPLETED	BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
NCT00621673	PHASE4	TERMINATED	Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
NCT00632814	PHASE4	COMPLETED	Russian Kogenate Pediatric Study
NCT00638001	PHASE4	COMPLETED	Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy
NCT00666406	PHASE4	COMPLETED	Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
NCT00765726	PHASE4	TERMINATED	Study Evaluating The Safety Of Xyntha In Usual Care Settings
NCT00884390	PHASE4	TERMINATED	Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
NCT00914459	PHASE4	COMPLETED	Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
NCT00916032	PHASE4	COMPLETED	Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A
NCT00927667	PHASE4	COMPLETED	Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
NCT00950170	PHASE4	COMPLETED	Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
NCT01064284	PHASE4	COMPLETED	Survey of Inhibitors in Plasma-Product Exposed Toddlers
NCT01748201	PHASE4	COMPLETED	Viscosupplementation in Patients With Hemophilic Arthropathy
NCT01810666	PHASE4	COMPLETED	Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
NCT01811875	PHASE4	TERMINATED	Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
NCT02170402	PHASE4	COMPLETED	China ADVATE PTP Study
NCT02314325	PHASE4	UNKNOWN	Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
NCT02479087	PHASE4	UNKNOWN	Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
NCT02492984	PHASE4	COMPLETED	PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
NCT02697370	PHASE4	COMPLETED	Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
NCT02727647	PHASE4	COMPLETED	Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients
NCT03103542	PHASE4	COMPLETED	Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
NCT03204539	PHASE4	TERMINATED	INdividualized ITI Based on Fviii(ATE) Protection by VWF
NCT03361137	PHASE4	TERMINATED	Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
NCT03379974	PHASE4	COMPLETED	Exercise Versus DDAVP in Patients With Mild Hemophilia A
NCT03449342	PHASE4	COMPLETED	Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
NCT03915080	PHASE4	COMPLETED	Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A
NCT03947567	PHASE4	UNKNOWN	Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
NCT04085458	PHASE4	COMPLETED	Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
NCT04396639	PHASE4	COMPLETED	Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
NCT04565236	PHASE4	COMPLETED	A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
NCT04621916	PHASE4	UNKNOWN	Preventing Inhibitor Recurrence Indefinitely